HIV prevention pill backed by US experts
Washington, May 12: A panel of US health experts has for the first time backed a drug to prevent HIV infection in healthy people.
The panel recommended US regulators approve the daily pill, Truvada, for use by people considered at high risk of contracting the Aids virus.
The US Food and Drug Administration (FDA) is not required to follow the panel's advice, but it usually does.
Some health workers and groups active in the HIV community have opposed the approval of the drug.
However, correspondents say the move could prove to be a new milestone in the fight against HIV/Aids.
Truvada is already approved by the FDA for people who are HIV-positive, and is taken along with existing anti-retroviral drugs.
Studies from 2010 showed that Truvada, made by California-based Gilead Sciences, reduced the risk of HIV in healthy gay men - and among HIV-negative heterosexual partners of people who are HIV-positive - by between 44% and 73%.
The Antiviral Drugs Advisory Committee, which advises the FDA, voted 19-3 in favour of prescribing the drug to the highest risk group - non-infected men who have sex with multiple male partners.
They also approved it, by majority votes, for uninfected people with HIV-positive partners and for other groups considered at risk of acquiring HIV through sexual activity.
The votes followed an 11-hour meeting of the panel in Silver Spring, Maryland, and a lengthy public comments session.
Opposition to the prospect of approving the drug is based on concerns that users could gain a false sense of security, and fears of a drug-resistant strain of HIV.
There is also concern that the high cost of Truvada could divert limited funding from more cost-effective options.
"We need to slow down. I care too much about my community not to speak my concerns," said Joey Terrill, of the Aids Healthcare Foundation, which campaigned against the drug's approval.
Nurse Karen Haughey told the panel: "Truvada needs to be taken every day, 100% of the time, and my experience as a registered nurse tells me that won't happen.
"In my eight years, not one patient that I've cared for has been 100% adherent."
But others welcomed the panel's recommendation.
"This brings us closer to a watershed for global HIV prevention efforts," said Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition, after the vote.
The FDA is expected to make its decision by 15 June.
In the UK, Sir Nick Partridge, chief executive of Terrence Higgins Trust, said: "There is no single method of prevention that can on its own stop the transmission of HIV.
"Adding Truvada to our existing range of prevention programmes, including safer sex campaigns, using condoms and regular testing for HIV is an exciting prospect.
"But we need to know if people at highest risk of infection are prepared to take a pill every day and whether there would be an increase in risk-taking behaviour which could outweigh the prevention effectiveness of Truvada."
He said a clinical trial to invesitgate these issues would begin in the UK in the autumn.
Lastupdate on : Sat, 12 May 2012 21:30:00 Makkah time
Lastupdate on : Sat, 12 May 2012 18:30:00 GMT
Lastupdate on : Sun, 13 May 2012 00:00:00 IST
- MORE FROM HEALTH
Chewdara (Beerwah), May 12: Minister for Agriculture, Ghulam Hassan Mir, on Saturday welcomed the response of the Hurriyat Conference for showing interest in day to day development scenario of the state More
- Srinagar City
ORPHANS OLDEST CLUB
As millions are spent on the greens miles apart, KGC decays under nose of authorities in this historic City
SKELETONS have started tumbling out of the Kashmir Golf Club (KGC) cupboards revealing the muck of alleged step-motherly treatment to this oldest golf course –dying unheard –under the nose of the government More
‘I will cooperate with SAC probe’
EMBEZZLEMENTS IN COOPERATIVES
Jammu, May 12: Reacting to the inquiry ordered by the State Accountability Commission (SAC) regarding the alleged embezzlements in the JK Cooperative Housing Corporation (JKCHC), Minister of State for More
Washington, May 12: A panel of US health experts has for the first time backed a drug to prevent HIV infection in healthy people. The panel recommended US regulators approve the daily pill, Truvada More
- Career and Counseling
THE previous issue of career counseling focused on courses offered in various institutes across India. In this concluding part, we bring to you information regarding various courses of journalism taught More